Recent human studies on the treatment of T1DM with a combination of an SGLT2 inhibitor and insulin have shown that SGLT2 inhibitors assist in controlling the glycaemic levels and reduce the insulin requirements (Evans et al., 2020). Here, INS is linked to type 1 diabetes mellitus.